Literature DB >> 8953151

mRNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in interface tissue around implants in loosening total hip arthroplasty.

N Ishiguro1, T Ito, K Kurokouchi, Y Iwahori, I Nagaya, Y Hasegawa, H Iwata.   

Abstract

Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase (TIMPs) play an important role in tissue destruction and remodeling. Nine samples of cement interface tissues from nine patients who had failed cemented total hip arthroplasty (THA) were obtained for revision of THA and analyzed on mRNA expression of MMPs and TIMPs. The preoperative serial radiographic examinations revealed an apparent clear zone around all implants. We excluded septic loosening as one of the factors affecting THA. Three samples were obtained from three different sites of the acetabular interface tissue in each patient. After extraction of total RNA from 27 samples, we used the reverse-transcriptional polymerase chain reaction (RT-PCR). mRNA of MMP-1, -2, -3, -9, and TIMP-1 and -2 was detected in the interface tissue. MMP-10 mRNA was not detected, yet MMP-1 and MMP-3 mRNA were commonly observed. TIMP-2 mRNA was also strongly expressed compared to TIMP-1. It was thus demonstrated that MMPs and TIMPs were produced locally in the cemented tissue of THA loosening. These findings may suggest that MMPs and TIMPs expressed around the implants play a critical role in the progression of aseptic loosening of THA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8953151     DOI: 10.1002/(SICI)1097-4636(199612)32:4<611::AID-JBM14>3.0.CO;2-G

Source DB:  PubMed          Journal:  J Biomed Mater Res        ISSN: 0021-9304


  7 in total

1.  UHMWPE oxidation increases matrix metalloproteinase-2 (MMP-2) release in human fibroblast.

Authors:  F Renò; M Cannas; L Costa
Journal:  J Mater Sci Mater Med       Date:  2002-04       Impact factor: 3.896

2.  Titanium particles up-regulate the activity of matrix metalloproteinase-2 in human synovial cells.

Authors:  Chunfeng Fu; Jing Xie; Ning Hu; Xi Liang; Rongfu Chen; Chunli Wang; Cheng Chen; Chunming Xu; Wei Huang; K-L Paul Sung
Journal:  Int Orthop       Date:  2013-11-24       Impact factor: 3.075

3.  Molecular pathology of total knee arthroplasty instability defined by RNA-seq.

Authors:  Eric A Lewallen; Christopher G Salib; William H Trousdale; Charlotte E Berry; Gabrielle M Hanssen; Joseph X Robin; Meagan E Tibbo; Anthony Viste; Nicolas Reina; Mark E Morrey; Joaquin Sanchez-Sotelo; Arlen D Hanssen; Daniel J Berry; Andre J van Wijnen; Matthew P Abdel
Journal:  Genomics       Date:  2017-11-22       Impact factor: 5.736

4.  Genetic susceptibility of early aseptic loosening after total hip arthroplasty: the influence of TIMP-1 gene polymorphism on Chinese Han population.

Authors:  Fengyu Pan; Shan Hua; Yi Luo; Dongjun Yin; Zhuang Ma
Journal:  J Orthop Surg Res       Date:  2014-12-03       Impact factor: 2.359

5.  Successful immunotherapy with matrix metalloproteinase-derived peptides in adjuvant arthritis depends on the timing of peptide administration.

Authors:  Jolanda H M van Bilsen; Josée P A Wagenaar-Hilbers; Maarten J F van der Cammen; Mariska E A van Dijk; Willem van Eden; Marca H M Wauben
Journal:  Arthritis Res       Date:  2002-05-07

6.  An experimental animal model of aseptic loosening of hip prostheses in sheep to study early biochemical changes at the interface membrane.

Authors:  Alexander O El-Warrak; Marvin Olmstead; Rebecca Schneider; Lorenz Meinel; Regula Bettschart-Wolfisberger; Margarete K Akens; Joerg Auer; Brigitte von Rechenberg
Journal:  BMC Musculoskelet Disord       Date:  2004-03-03       Impact factor: 2.362

Review 7.  Extracellular matrix degradation and tissue remodeling in periprosthetic loosening and osteolysis: focus on matrix metalloproteinases, their endogenous tissue inhibitors, and the proteasome.

Authors:  Spyros A Syggelos; Alexios J Aletras; Ioanna Smirlaki; Spyros S Skandalis
Journal:  Biomed Res Int       Date:  2013-06-19       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.